AbbVie Sees FY23 Adj. EPS Including Q2 Impact Of Acquired IPR&D And Milestones Expense Of $10.57 - $10.97
Portfolio Pulse from Benzinga Newsdesk
AbbVie has projected its FY23 adjusted EPS, including the Q2 impact of acquired IPR&D and milestones expense, to be between $10.57 and $10.97. The company also expects its Q2 adjusted EPS, including the impact of acquired IPR&D and milestones expense, to be between $2.75 and $2.85.
July 06, 2023 | 8:24 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AbbVie's FY23 and Q2 adjusted EPS projections, including the impact of acquired IPR&D and milestones expense, are $10.57-$10.97 and $2.75-$2.85 respectively.
The news is directly about AbbVie's earnings forecast, which is a key factor that investors consider when making investment decisions. However, without additional context such as market expectations or comparison with previous forecasts, it's hard to determine the direction of the stock price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100